What is the best‑evidence medication for eosinophilic asthma, and what investigations and stepwise treatment approach should be followed?

Eosinophilic Asthma: Best Evidence Medication, Investigations, and Stepwise Approach

For severe eosinophilic asthma, mepolizumab (anti-IL-5) is the medication with the strongest evidence, demonstrating significant reductions in exacerbations (42%), improvements in lung function (FEV1), and favorable safety profiles, particularly at 75-100 mg dosing. 1

Key Investigations

Essential Biomarker Assessment

• Blood eosinophil count (BEC): The most accessible and validated biomarker for treatment selection 2

  • Use ≥150 cells/μL as the threshold for initiating anti-IL-5 therapy 3
  • Historical values ≥300 cells/μL also predict response 2
  • Interpret serially, accounting for corticosteroid exposure which suppresses counts 4

• Fractional exhaled nitric oxide (FeNO): Indicates type 2 airway inflammation 5

  • ≥19.5 ppb suggests likelihood of response to anti-IgE therapy 3
  • Useful for confirming eosinophilic phenotype when combined with BEC

• Spirometry with bronchodilator response: Confirms airflow limitation and reversibility

• Methacholine challenge testing: When spirometry is normal but asthma suspected 6

Additional Assessments

• Evaluate for type 2 comorbidities: chronic rhinosinusitis with nasal polyps, atopic dermatitis, eosinophilic esophagitis 7
• Assess exacerbation history, oral corticosteroid (OCS) exposure, and quality of life impact 8

Stepwise Treatment Approach

Step 1: Initial Management

Start with inhaled corticosteroids (ICS) plus long-acting beta-agonists (LABA) as foundation therapy 9, 6

• Optimize inhaled therapy before escalating to biologics
• Ensure proper inhaler technique and adherence
• Continue for 8-12 weeks before assessing response

Step 2: Assess for Severe Eosinophilic Asthma

Criteria indicating need for biologic therapy:

• Uncontrolled symptoms despite high-dose ICS/LABA (GINA step 4-5)
• ≥2 exacerbations requiring systemic corticosteroids in past year
• BEC ≥150 cells/μL (or historical ≥300 cells/μL) 3, 2
• Chronic OCS dependence or frequent OCS bursts
• Significantly impaired quality of life 7

Step 3: Biologic Selection Algorithm

For severe eosinophilic asthma with BEC ≥150 cells/μL:

• First-line: Mepolizumab (anti-IL-5) 75-100 mg subcutaneous every 4 weeks 10, 1
  • Strongest evidence for exacerbation reduction (42% decrease)
  • Best safety profile at this dose
  • Enhanced efficacy when baseline eosinophils ≤300 cells/μL 1

Alternative anti-IL-5/IL-5R options:

• Benralizumab (anti-IL-5Rα): Consider if BEC ≥300 cells/μL 11
  • More rapid eosinophil depletion
  • Every 8-week dosing after loading
• Reslizumab (anti-IL-5): If BEC ≥400 cells/μL 11
  • IV administration may limit use

For specific phenotypes:

• Dupilumab (anti-IL-4Rα): When eosinophilic asthma coexists with chronic rhinosinusitis with nasal polyps or atopic dermatitis 7, 11

  • Also effective in corticosteroid-dependent asthma regardless of eosinophil level 3

• Omalizumab (anti-IgE): When allergic component predominates (elevated IgE >30 IU/mL, positive skin tests) 11

  • Preferred in females planning pregnancy 7
  • Consider if FeNO ≥19.5 ppb and eosinophils ≥260 cells/μL 3

• Tezepelumab (anti-TSLP): For type 2 and non-type 2 severe asthma 7

  • Broadest indication but less specific evidence for eosinophilic phenotype

Step 4: Adjunctive Therapies

Add inhaled tiotropium (long-acting muscarinic antagonist) for persistent symptoms despite ICS/LABA 3

Consider leukotriene receptor antagonist (LTRA) before escalating to systemic corticosteroids in refractory cases 6

Chronic macrolide therapy may reduce exacerbations in persistently symptomatic patients, irrespective of phenotype 3

Step 5: Refractory Disease Management

If inadequate response after 4 months of biologic therapy:

• Reassess diagnosis and exclude alternative causes
• Verify treatment adherence and proper inhaler technique
• Check for persistent eosinophilia despite therapy
• Consider switching to alternative biologic mechanism 10
  • If on anti-IL-5, switch to dupilumab or tezepelumab
  • If on omalizumab, switch to anti-IL-5 agent

Short course systemic corticosteroids (1-2 weeks) for severe exacerbations, followed by rapid taper back to maintenance therapy 6

Critical Pitfalls to Avoid

1. Do not rely on sputum eosinophils for treatment decisions—blood eosinophils are the validated biomarker 2

2. Do not check eosinophils while patient is on systemic corticosteroids—this artificially suppresses counts and invalidates interpretation 4

3. Do not use single eosinophil measurement—obtain serial values over time, as counts fluctuate 4

4. Do not discontinue ICS when starting biologics—maintain foundation therapy 8

5. Do not expect immediate response—biologics require 4-16 weeks for full effect 7

6. Do not use traditional immunomodulators (azathioprine, 6-mercaptopurine) or anti-TNF agents—these lack efficacy in eosinophilic asthma 12

Monitoring and De-escalation

After achieving remission (≥3 months of control):

• Consider cautious ICS dose reduction under close supervision 8
• Maintain biologic therapy—discontinuation frequently leads to loss of control 8
• Monitor BEC, FeNO, symptoms, and lung function quarterly
• Favorable predictors for successful de-escalation: shorter disease duration, fewer prior exacerbations, lower chronic OCS exposure, preserved FEV1 8

The evidence strongly supports mepolizumab as first-line biologic therapy for severe eosinophilic asthma based on the most robust clinical trial data, favorable safety profile, and validated biomarker thresholds for patient selection.